Pfizer Inc. (PFE) PEG Ratio: 0.07
Is Pfizer Inc.’s PEG ratio high or low?
Pfizer Inc.'s PEG ratio of 0.07 is 56% below its 5-year average of 0.16, near the low end of its 5-year range (0.07–0.24).
The PEG ratio for Pfizer Inc. (PFE) is 0.07. It is equal to its 12-month average by 0.00% (0.07).
PFE PEG Ratio Chart
PFE Average PEG Ratio Chart
PFE Current vs Average PEG Ratio Chart
PFE PEG Ratio Metrics
PEG RATIO
0.07
PEG RATIO AVG TTM
0.07
PEG RATIO AVG 3Y
0.13
PEG RATIO AVG 5Y
0.16
PEG RATIO AVG 10Y
1.05
PEG RATIO AVG 15Y
1.46
PEG RATIO AVG 20Y
3.30
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
-47.50%
CURRENT VS 5Y AVG
-56.25%
CURRENT VS 10Y AVG
-93.33%
CURRENT VS 15Y AVG
-95.20%
CURRENT VS 20Y AVG
-97.88%
PFE Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | — | 0.07 | 0.07 | 0.13 | 0.16 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 3.17 | 3.02 | 2.60 | 2.27 |
| Gilead Sciences, Inc. (GILD) | $155.82B | 0.01 | 0.01 | 0.38 | 0.25 |
| Abbott Laboratories (ABT) | $158.94B | 0.11 | 0.11 | 0.36 | 0.87 |
| Danaher Corporation (DHR) | $133.37B | 2.01 | 1.21 | 1.11 | 1.91 |
| CVS Health Corporation (CVS) | $123.84B | 0.13 | 0.13 | 1.20 | 1.16 |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 0.06 | 0.24 | 0.24 | 0.18 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 1.69 | 2.58 | 1.90 | 1.47 |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 4.51 | 4.57 | 4.57 | 2.77 |
| Amgen Inc. (AMGN) | $185.96B | 0.26 | 0.26 | 2.94 | 2.94 |
Growth-Adjusted Valuation
PEG Ratio
0.07
P/E Ratio
19.6
Pfizer Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. PEG Ratio FAQ
- What is the PEG ratio for Pfizer Inc. (PFE)?
- The PEG ratio for PFE stock is 0.07.
- Is Pfizer Inc.'s PEG ratio high or low?
- Pfizer Inc.'s PEG ratio of 0.07 is 56% below its 5-year average of 0.16, near the low end of its 5-year range (0.07–0.24).
- What is the TTM average PEG ratio for Pfizer Inc. (PFE)?
- The TTM average PEG ratio for PFE stock is 0.07.
- What is the 3Y average PEG ratio for Pfizer Inc. (PFE)?
- The 3Y average PEG ratio for PFE stock is 0.13.
- What is the 5Y average PEG ratio for Pfizer Inc. (PFE)?
- The 5Y average PEG ratio for PFE stock is 0.16.
- What is the 10Y average PEG ratio for Pfizer Inc. (PFE)?
- The 10Y average PEG ratio for PFE stock is 1.05.
- What is the 15Y average PEG ratio for Pfizer Inc. (PFE)?
- The 15Y average PEG ratio for PFE stock is 1.46.
- What is the 20Y average PEG ratio for Pfizer Inc. (PFE)?
- The 20Y average PEG ratio for PFE stock is 3.30.
Pfizer Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.07 |
| 2022-12-31 | 0.22 |
| 2021-12-31 | 0.11 |
| 2019-12-31 | 0.24 |
| 2017-12-31 | 0.05 |
| 2016-12-31 | 5.61 |
| 2013-12-31 | 0.57 |
| 2012-12-31 | 1.00 |
| 2011-12-31 | 2.27 |
| 2009-12-31 | 4.44 |
| 2008-12-31 | 27.83 |
| 2006-12-31 | 0.34 |
| 2004-12-31 | 0.09 |
| 2002-12-31 | 1.06 |
| 2001-12-31 | 0.28 |
| 1998-12-31 | 0.83 |
| 1997-12-31 | 3.52 |
| 1996-12-31 | 1.06 |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla